Small-molecule therapeutics in rheumatoid arthritis: Scientific rationale, efficacy and safety

Best Practice and Research: Clinical Rheumatology

Volumn 28, Issue 4, 2014, Pages 605-624

  Meier, Florian M P ^a,b   McInnes, Iain B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Arthritis; Inflammation; Kinase; Kinase inhibitor; Rheumatoid arthritis; Signal transduction; Small molecule; Tofacitinib

Indexed keywords

BRUTON TYROSINE KINASE INHIBITOR; JANUS KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN KINASE SYK INHIBITOR; ANTIRHEUMATIC AGENT; PROTEIN KINASE INHIBITOR;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; INTRACELLULAR SIGNALING; META ANALYSIS (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; DRUG DEVELOPMENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DISCOVERY; HUMANS; PROTEIN KINASE INHIBITORS;

EID: 84927551421     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2014.10.017     Document Type: Review

References (103)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med Dec 8 2011;365(23):2205-19.
2. Tak PP. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatol (Oxford) Mar 16 2012;51(4):600-9.
3. Sweeney SE, Firestein GS. Primer: signal transduction in rheumatic diseaseda clinician's guide. Nat Clin Pract Rheumatol Nov 2007;3(11):651-60.
4. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med Aug 9 2012;367(6):495-507.
5. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum Feb 2009;60(2):317-20.
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 Apr.5;344(14):1031-7.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med Jan 11 2007;356(2):115-24.
8. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med Mar 1 2012;366(9):799-807.
9. Lee JC, Griswold DE, Votta B, et al. Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002. Int J Immunopharmacol 1988;10(7):835-43.
10. Simmons DL. Targeting kinases: a new approach to treating inflammatory rheumatic diseases. Curr Opin Pharmacol Elsevier Ltd Jun 1 2013;13(3):426-34.
11. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature Dec 1994;372(6508):739-46.
12. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol Aug 2004;4(4):372-7.
13. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature Mar 1 2001;410(6824):37-40.
14. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell Oct 13 2000;103(2):239-52.
15. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov Jul 2003;2(7): 554-65.
16. Patterson H, Nibbs R, McInnes I, et al. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol Mar 6 2014;176(1):1-10.
17. Coulombe P, Meloche S. Atypical mitogen-activated protein kinases: structure, regulation and functions. Biochim Biophys Acta Aug 2007;1773(8):1376-87.
18. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal Jan 2000;12(1):1-13.
19. Korb A, Tohidast-Akrad M, Cetin E, et al. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum Sep 2006;54(9):2745-56.
20. Hale KK, Trollinger D, Rihanek M, et al. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J Immunol Apr 1 1999;162(7):4246-52.
21. Chabaud-Riou M, Firestein GS. Expression and activation of mitogen-activated protein kinase kinases-3 and -6 in rheumatoid arthritis. Am J Pathol Jan 2004;164(1):177-84.
22. Inoue T, Hammaker D, Boyle DL, et al. Regulation of p38 MAPK by MAPK kinases 3 and 6 in fibroblast-like synoviocytes. J Immunol Apr 1 2005;174(7):4301-6.
23. Gaestel M. What goes up must come down: molecular basis of MAPKAP kinase 2/3-dependent regulation of the inflammatory response and its inhibition. Biol Chem Oct 2013;394(10):1301-15.
24. Carballo E. Feedback inhibition of macrophage tumor necrosis factor- production by tristetraprolin. Science Aug 14 1998;281(5379):1001-5.
25. Badger AM, Griswold DE, Kapadia R, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum Jan 2000;43(1):175-83.
26. Nishikawa M, Myoui A, Tomita T, et al. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum Sep 2003;48(9):2670-81.
27. Cohen SB, Cheng T-T, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum Feb 2009;60(2):335-44.
28. Genovese MC, Cohen SB, Wofsy D, et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol May 2011;38(5):846-54.
29. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum May 2009;60(5):1232-41.
30. Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol Mar 2006;4(3): 325-34.
31. Hammaker D, Firestein GS. "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis Jan 2010; 69(Suppl. 1):i77-82.
32. Salgado E, Maneiro JR, Carmona L, et al. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis Apr 4 2014;73(5):871-82.
33. Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel Jul 2005;8(4):421-30.
34. Newby LK, Marber MS, Melloni C, et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non- ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet Sep.27 2014;384(9949):1187-95.
35. Roberts A. Acute coronary syndromes: promising data for losmapimod in NSTEMI. Nat Rev Cardiol Aug 2014;11(8): 436.
36. Mocsai A, Ruland J, Tybulewicz VLJ. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol Jun 2010;10(6):387-402.
37. Sada K, Takano T, Yanagi S, et al. Structure and function of Syk protein-tyrosine kinase. J Biochem Aug 2001;130(2): 177-86.
38. Yanagi S, Inatome R, Takano T, et al. Syk expression and novel function in a wide variety of tissues. Biochem Biophys Res Commun Nov 2 2001;288(3):495-8.
39. Wong BR, Grossbard EB, Payan DG, et al. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs Jul 2004;13(7):743-62.
40. Cha H-S, Boyle DL, Inoue T, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther May 2006;317(2):571-8.
41. Braselmann S, Taylor V, Zhao H, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther Dec 2006;319(3): 998-1008.
42. Pine PR, Chang B, Schoettler N, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol Sep 2007;124(3):244-57.
43. Coffey G, DeGuzman F, Inagaki M, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther Feb 2012;340(2):350-9.
44. Rossi AB, Herlaar E, Braselmann S, et al. Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J Allergy Clin Immunol Sep 2006;118(3):749-55.
45. Matsubara S, Li G, Takeda K, et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med Jan 1 2006;173(1):56-63.
46. Zhu Y, Herlaar E, Masuda ES, et al. Immunotoxicity assessment for the novel spleen tyrosine kinase inhibitor R406. Toxicol Appl Pharmacol Jun 15 2007;221(3):268-77.
47. Lucas MC, Goldstein DM, Hermann JC, et al. Rational design of highly selective spleen tyrosine kinase inhibitors. J Med Chem Dec 13 2012;55(23):10414-23.
48. Jakus Z, Simon E, Balázs B, et al. Genetic deficiency of Syk protects mice from autoantibody-induced arthritis. Arthritis Rheum Jul 2010;62(7):1899-910.
49. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum Feb 2011;63(2):337-45.
50. Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med Sep 30 2010;363(14):1303-12.
51. Weinblatt ME, Genovese MC, Ho M, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol Sep 15 2014. http://dx.doi.org/10.1002/art.38851.
52. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum Nov 2008;58(11):3309-18.
53. Taylor PC, Genovese MC, Greenwood M, et al. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis Jul 29 2014. http://dx.doi.org/10.1136/annrheumdis- 2014-205361.
54. Genovese MC, van der Heijde DM, Keystone E, et al. A phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-a antagonist. J Rheumatol Sep.15 2014.
55. Nijjar JS, Tindell A, McInnes IB, et al. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatol (Oxford) Aug 12 2013;52(9):1556-62.
56. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med Jan 6 2011;364(1):83-4.
57. Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood Apr 2 2009;113(14):3154-60.
58. Kazerounian S, Duquette M, Reyes MA, et al. Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. Blood Apr 28 2011;117(17):4658-66.
59. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med Jan 10 2013;368(2):161-70.
60. Dawson MA, Bannister AJ, Göttgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature Oct 8 2009;461(7265):819-22.
61. Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer Sep 2007;7(9):673-83.
62. Scott LM, TongW, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med Feb 1 2007;356(5):459-68.
63. Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature Sep 7 1995;377(6544):65-8.
64. Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of janus kinases. Immunol Rev Jun 2008;223(1):132-42.
65. Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis Feb 2006;65(2): 149-56.
66. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med Sep 16 2010;363(12):1117-27.
67. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med Mar 1 2012;366(9):787-98.
68. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med Oct 13 2011;365(15):1455-7.
69. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol May 1 2010;184(9):5298-307.
70. Shi Jack G, Chen Xuejun, Lee Fiona, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol December 2014;54(12):1354-61.
71. Vanhouette F, Mazur M, van der Aa A. Selective JAK1 inhibition in the treatment of rheumatoid arthritis: proof of concept with GLPG0634. Arthritis Rheum Oct 1 2012;64(10 (Suppl.)). S1051.
72. Kyttaris VC. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther 2012;6:245-50.
73. Milici AJ, Kudlacz EM, Audoly L, et al. Cartilage preservation by inhibition of janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008;10(1):R14.
74. Yarilina A, Xu K, Chan C, et al. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum Dec 2012;64(12):3856-66.
75. Onuora S. Experimental arthritis: JAK inhibition with tofacitinib curbs RANKL-induced joint damage. Nat Rev Rheumatol Oct 2012;8(10):564.
76. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690, 550, an orally active janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis Feb 2010;69(2):413-6.
77. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP- 690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum Apr 2012;64(4):970-81.
78. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum Jul 2009;60(7):1895-905.
79. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP- 690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum Mar 2012;64(3):617-29.
80. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med Jun 19 2014; 370(25):2377-86.
81. Onuora S. Rheumatoid arthritis: can tofacitinib be used as first-line monotherapy for RA? Nat Rev Rheumatol Nat Publ Group Jul 8 2014;10(8):443.
82. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med Aug 9 2012;367(6):508-19.
83. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet Feb 2013;381(9865):451-60.
84. Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med Aug 20 2013;159(4):253-61.
85. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum Mar 2013;65(3):559-70.
86. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol Oct 2014;66(10):2675-84.
87. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol Nov 2006; 6(11):836-48.
88. Satterthwaite AB, Li Z, Witte ON. Btk function in B cell development and response. Semin Immunol Aug 1998;10(4): 309-16.
89. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatol (Oxford) Feb 2001;40(2):205-11.
90. Edwards JCW, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med Jun 17 2004;350(25):2572-81.
91. Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol Apr 2013;131(4):959-71.
92. Kurosaki T, Shinohara H, Baba Y. B cell signaling and fate decision. Annu Rev Immunol 2010;28:21-55.
93. Mohamed AJ, Yu L, Bäckesjö C-M, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev Mar 2009;228(1):58-73.
94. Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human Xlinked agammaglobulinemia. Cell Jan 29 1993;72(2):279-90.
95. Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of unique region of bruton's tyrosine kinase in immunodeficient XID mice. Science Jul 16 1993;261(5119):358-61.
96. Khan WN, Alt FW, Gerstein RM, et al. Defective B cell development and function in Btk-deficient mice. Immunity Sep 1995;3(3):283-99.
97. Kerner JD, Appleby MW, Mohr RN, et al. Impaired expansion of mouse B cell progenitors lacking Btk. Immunity Sep 1995;3(3):301-12.
98. Jansson L, Holmdahl R. Genes on the X chromosome affect development of collagen-induced arthritis in mice. Clin Exp Immunol Dec 1993;94(3):459-65.
99. Whang JA, Chang BY. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug discovery today. Elsevier Ltd; Apr.22 2014. p. 1-5.
100. Bartok B, Hammaker D, Firestein GS. Phosphoinositide 3-kinase d regulates migration and invasion of synoviocytes in rheumatoid arthritis. J Immunol Mar 1 2014;192(5):2063-70.
101. Camps M, Rückle T, Ji H, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med Sep 2005;11(9):936-43.
102. Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol Mar 2007;7(3):191-201.
103. Cantley LC. The phosphoinositide 3-kinase pathway. Science May 31 2002;296(5573):1655-7.